Quality of Life in Women Using LARC Contraception
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Etonogestrel Implant, Levonorgestrel Intrauterine Device, Copper Intrauterine Device.
- Who it may be relevant to
- Registry conditions: Quality of Life. Basic parameters: 18 years — 45 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Quality of Life in Women Using LARC Contraception: Cross-Sectional Study
Overview
assessment of quality of life in women using LARC
Detailed description
The ability to control one's fertility is a cornerstone of reproductive health and personal autonomy, fundamentally influencing women's educational, economic, and social trajectories. Modern contraception provides this control, offering a diverse range of methods that allow women and couples to plan if and when to have children. The choice of contraceptive method is a deeply personal decision, often guided by a complex interplay of medical history, lifestyle, personal values, and an individual's priorities regarding efficacy, convenience, and potential side effects (Bangar \& Bansal, 2023).
Long-Acting Reversible Contraception (LARC) emerged as a highly effective and increasingly popular category. LARC methods are distinguished by their requirement for administration by a healthcare provider but offer protection against pregnancy for an extended period, ranging from three to ten years, without any ongoing user action. Their "forget-and-forget" nature eliminates the need for daily, weekly, or monthly adherence, resulting in typical-use effectiveness rates that rival those of permanent sterilization. (Francis et al., 2024).
While the clinical effectiveness of LARC in preventing pregnancy is well-established, a comprehensive understanding of its impact must extend beyond this singular outcome to encompass the broader concept of quality of life (QoL). Quality of life is a multidimensional construct that includes physical well-being, psychological state, social relationships, and environmental factors. For a woman using contraception, QoL is affected not only by her confidence in avoiding an unintended pregnancy but also by her experience with method-related side effects (such as changes in bleeding patterns, mood, or weight), the convenience of use, and the overall sense of control over her reproductive health. (Alsammani \& Ahmed, 2023)
Interventions
- Device Etonogestrel Implant
Insertion of a single etonogestrel-releasing subdermal contraceptive implant in the upper arm by a trained healthcare provider according to standard clinical practice. - Device Levonorgestrel Intrauterine Device
Insertion of a levonorgestrel-releasing intrauterine device into the uterine cavity by a trained healthcare provider for long-acting contraception. - Device Copper Intrauterine Device
Insertion of a copper intrauterine device into the uterine cavity by a trained healthcare provider as a non-hormonal long-acting contraceptive method.
Primary outcome measures
- Change in World Health Organization Quality of Life-BREF (WHOQOL-BREF) Total Score at 3 Months Post-Method Initiation [Time frame: Baseline and 3 months after contraceptive method initiation]
Secondary outcome measures (4)
- Proportion of Participants Reporting Dysmenorrhea Assessed by Visual Analogue Scale (VAS) for Pain [Time frame: Baseline and 3 months after method initiation]
- Mean Dysmenorrhea Severity Score Assessed by Visual Analogue Scale (VAS) [Time frame: Baseline and 3 months after method initiation]
- Change in Female Sexual Function Index (FSFI) Total Score [Time frame: Baseline and 3 months after method initiation]
- Change in Depression Subscale Score of the Depression Anxiety Stress Scales-21 (DASS-21) [Time frame: Baseline and 3 months after method initiation]
Eligibility criteria
Inclusion criteria
- women aged 18 to 45 years,
women used LARC contraception,
women agreed to participate.
Exclusion criteria
- women using non LARC contraception,
women had any psychiatric disorder
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-crossover
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07509138 · LARC-Contraception-QoL